Nonetheless, tipifarnib seemed efficient regardless of HRAS hotspot mutation, as it inhibited activity on patient derived xenograft HNSCC models harbouring Q61L, G12C, G12S, G13R, and K117N mutations [31]. The gene discussed is HRAS; the disease is head and neck squamous cell carcinoma.